Understanding NIH Paylines: How Institutes Decide Which Scores Get Funded and What You Can Do About It

For decades, the arithmetic was brutal but legible. Score below the 10th percentile at the National Cancer Institute, and your R01 would probably get funded. Score a 12th at NIAID, and you had a solid shot. Score a 20th at NIDDK as an early-stage investigator, and you were golden. Every fiscal year, most of NIH's 27 institutes and centers published a single number — a percentile cutoff called a payline — that told researchers, with reasonable confidence, whether they'd cleared the bar. That system is now gone.

In November 2025, NIH announced its Unified Funding Strategy, effective with the January 2026 advisory council round. The most consequential change: institutes will no longer rely on or publish paylines. Instead, every funding decision must weigh six factors — scientific merit, NIH mission alignment, portfolio balance, career stage, geographic distribution, and stewardship of available funds. A strong percentile score no longer guarantees an award. A score just outside the old cutoff no longer guarantees rejection.

The elimination of paylines arrived at the worst possible moment. NIH has funded 74% fewer new competitive awards so far in FY2026 compared with the four-year average. R01-equivalent success rates fell from 22% in FY2023 to an estimated 13% in FY2025. Early-stage investigator success rates collapsed from 29.8% to 18.5% over the same period. Researchers are now navigating the tightest funding environment in modern NIH history — without the one navigational tool they used to have.

What Paylines Were, and Why They Mattered

A payline is a percentile score threshold set independently by each NIH institute or center at the start of a fiscal year. Applications scoring at or below the payline were, in most cases, funded automatically. Applications scoring above were either declined or routed into a discretionary review process called select pay.

The percentile itself ranks an application against all others reviewed by the same study section over its last three meetings. Lower is better — a 5th percentile means your application outscored 95% of the pool. Each institute then set its own cutoff based on its budget, its commitment to noncompeting renewals, and its appetite for new awards.

The variation across institutes was significant. In FY2024, NIAID set its R01 payline around the 12th percentile. NINDS set theirs at the 11th. NCI held at the 10th for established investigators but maintained a more generous line for early-stage investigators. NIAMS funded competing R01s through the 8th percentile, with a 15th percentile cutoff for ESIs. NIDDK maintained one of the most generous ESI paylines at the 25th percentile — seven points above its regular line.

That dispersion created a paradox familiar to any grant strategist: the same application, with the same score from the same study section, could be funded at one institute and rejected at another. A 14th-percentile R01 on infectious disease mechanisms would sail through at NIAID but die at NINDS. The payline wasn't a measure of scientific quality. It was a measure of institute budget and priority.

NIGMS, the fourth-largest institute by budget, never used paylines at all. Its policy was — and remains — to evaluate each application individually, weighing factors like portfolio breadth, the investigator's total existing support, and whether funding a second R01 for one lab would come at the expense of a first for another. NIGMS openly stated its goal was to maximize the number of funded investigators, not to maximize the number of funded grants. That philosophy made it an outlier for years. Now the entire agency has adopted something closer to NIGMS's approach.

The Mechanics of Discretionary Funding

Even when paylines existed, they never told the whole story. Every institute reserved a portion of its budget — typically 10% to 20% of new awards — for applications scoring beyond the payline. This process, called select pay or exception funding, was how institutes exercised scientific judgment beyond the raw score.

At NINDS, select pay candidates needed to fall within roughly 10 percentile points of the payline, come from an early-stage investigator, or address a high-priority gap in the institute's portfolio. Program officers nominated applications; advisory council reviewed the nominations. Investigators couldn't apply for select pay and weren't notified they were being considered.

NIAID used a similar system, with program staff identifying applications that scored outside the payline but addressed critical mission needs — emerging pathogens, vaccine development, antimicrobial resistance. The institute's bridge award program offered a parallel lifeline: partial funding to sustain productive labs while investigators revised and resubmitted.

The existence of select pay meant that paylines were always softer than they appeared. A researcher scoring five points above the published line might still get funded if their work happened to align with a program officer's portfolio gap. But this flexibility was modest, unpublicized, and impossible to plan around. Most applicants treated the payline as a hard wall.

What the Unified Funding Strategy Actually Changes

The November 2025 announcement formalized what some institutes — NIGMS, NICHD, parts of NIMH — had already been practicing informally. The six mandated criteria (merit, mission, portfolio balance, career stage, geography, stewardship) are not new concepts. What's new is that every institute must now apply all six, and none can fall back on a simple percentile threshold as their primary decision mechanism.

In February 2026, NIH published "Institute and Center Director Perspectives" on implementing the framework. The language was careful. Directors emphasized that peer review remains the foundation, that the unified strategy adds context rather than replacing merit, and that a new transparency portal would eventually let applicants see how decisions were made across institutes.

Critics see it differently. A Science magazine investigation published shortly after the announcement quoted NIH program officers who feared the policy "opens the door wide for abuse from an administration that has definitely not earned our trust regarding their scientific judgment." The concern is straightforward: when a single percentile number determines funding, political interference is difficult. When six subjective factors must be weighed by institute leadership, political preferences can hide inside terms like "mission alignment" and "geographic balance."

The timing compounds the anxiety. NIH Director Jay Bhattacharya, appointed in 2025, has publicly emphasized redirecting research toward areas the administration considers underserved — including geographic distribution of funding beyond the coasts. The unified strategy's geographic criterion arrived simultaneously with an administration that has made geographic equity a stated priority, making it difficult to separate technocratic reform from political redirection.

For researchers, the practical consequence is uncertainty. Virginia Tech's Office of Research issued guidance noting that investigators can no longer estimate their funding probability from a published payline, institutions can no longer forecast grant revenue reliably, and early-career scientists can no longer make informed decisions about resubmission timing or job searches based on where their score landed relative to a known cutoff.

The FY2025 Collapse That Made It Worse

The payline system didn't end gracefully. It ended amid the most severe funding disruption in NIH's modern history, making it impossible to judge the new system on its own merits.

Three forces converged in FY2025. First, an OMB spending hold delayed release of appropriated funds for months. Second, the multiyear forward-funding policy — requiring that half of competing grant funds be committed upfront across the entire award period — consumed dollars that would otherwise support new awards. Third, staff losses from Schedule Policy/Career reclassifications reduced the grant-processing workforce.

The results were immediate. NCI's effective payline crashed from the 10th percentile in FY2024 to roughly the 4th percentile in the second half of FY2025. NIAID's interim payline dropped to the 8th. NINDS fell from 11 to 8. At NCI, the shift from one-in-ten to one-in-twenty-five was not a gradual tightening but a mid-year collapse that left hundreds of applications — scored, reviewed, and recommended — unfunded.

As of March 17, 2026, NIH had issued 74% fewer new competitive awards than the four-year average for the same period. Dollar values were 62% below historical norms. A STAT News survey of NIH-funded researchers found that 45% had experienced delays in existing awards and 15% had experienced outright terminations.

Against this backdrop, eliminating paylines feels less like reform and more like removing the speedometer from a car that's already off the road.

How to Navigate Funding Without a Payline

The disappearance of a published number doesn't mean the underlying dynamics vanished. Institutes still have budgets, still receive more scored applications than they can fund, and still must draw a line somewhere. The line is just no longer visible.

Track your institute's actual funding patterns. NIH RePORT still publishes success rates, award counts, and funding levels by institute. Even without a formal payline, you can infer the effective cutoff by comparing the number of funded R01s against the distribution of scores in your study section. If an institute funded 180 competing R01s last year and your study section typically reviews 400 applications in that institute's domain, the effective success rate tells you more than any published payline ever did.

Talk to program officers before you submit. This was always good advice. Now it's essential. Program officers know their institute's current priorities, portfolio gaps, and how the unified strategy is being interpreted internally. They can't tell you whether your application will be funded, but they can tell you whether your research area is one the institute is actively trying to grow — which, under the new framework, matters as much as your score.

Consider institute assignment strategically. On the PHS Assignment Request Form, you can request up to three institutes for primary assignment. The Center for Scientific Review honors these requests when the science fits. If your research plausibly spans two institutes — say, a neurodegenerative disease study that could land at NINDS or NIA — understanding which institute has more budget flexibility or a stronger programmatic interest in your specific angle can meaningfully shift your odds.

Leverage early-stage investigator status while it still carries weight. Every institute maintained a more generous payline for ESIs when paylines existed, and the unified strategy explicitly lists career stage as a decision factor. NIDDK's ESI payline was 25th percentile when the regular line was 18th. That differential hasn't disappeared — it's just embedded in a more opaque process. If you qualify as an ESI, make sure your application clearly identifies you as one.

Strengthen your resubmission over scattering new applications. In a tighter environment, the A1 resubmission — a revised application that directly addresses reviewer critiques — remains the highest-probability path to funding. NIH data consistently show that resubmissions score better than initial submissions. With fewer awards available and more discretionary factors in play, a strong resubmission that demonstrates responsiveness to peer review signals the kind of scientific rigor that program officers look for when making select-pay-style decisions.

Diversify beyond NIH. NSF, DOD's Congressionally Directed Medical Research Programs, DOE, and private foundations all fund biomedical research. The MacArthur Foundation, Gates Foundation, Howard Hughes Medical Institute, and dozens of disease-specific foundations offer mechanisms that don't depend on NIH's budget. When NIH's effective success rate drops below 15%, treating it as your sole funding source is a strategic error.

What Comes Next

NIH has promised a transparency portal that will show how funding decisions are being made under the unified strategy — which factors weighed most heavily, how geographic and career-stage considerations were applied, and how the new system compares to payline-era outcomes. That portal has not yet launched. Until it does, researchers are operating in an information vacuum that NIH created by removing the old system before the replacement was fully built.

The deeper question is whether the unified strategy will survive its political context. If the next administration reverses course, paylines could return. If the current approach persists, institutes may gradually develop their own informal benchmarks — unwritten but widely understood cutoffs that function like paylines without the name. NIGMS operated this way for years, and experienced investigators learned to read the signals.

In the meantime, the researchers who will fare best are the ones who stop treating the funding decision as a single number and start treating it as a portfolio problem: multiple institutes, multiple mechanisms, multiple funders, multiple submission cycles. The payline era rewarded precision — hit the number and you're in. The post-payline era rewards breadth, relationships, and strategic positioning across an opaque landscape. Platforms like Granted can help researchers scan that broader landscape — federal and foundation opportunities together — so that no single institute's funding decision determines whether the work continues.